These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 32052640)
1. Disclosure of Amyloid Status for Risk of Alzheimer Disease to Cognitively Normal Research Participants With Subjective Cognitive Decline: A Longitudinal Study. Wake T; Tabuchi H; Funaki K; Ito D; Yamagata B; Yoshizaki T; Nakahara T; Jinzaki M; Yoshimasu H; Tanahashi I; Shimazaki H; Mimura M Am J Alzheimers Dis Other Demen; 2020; 35():1533317520904551. PubMed ID: 32052640 [TBL] [Abstract][Full Text] [Related]
3. The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline. Wake T; Tabuchi H; Funaki K; Ito D; Yamagata B; Yoshizaki T; Kameyama M; Nakahara T; Murakami K; Jinzaki M; Mimura M Int Psychogeriatr; 2018 May; 30(5):635-639. PubMed ID: 29094656 [TBL] [Abstract][Full Text] [Related]
4. Safety of disclosing amyloid status in cognitively normal older adults. Burns JM; Johnson DK; Liebmann EP; Bothwell RJ; Morris JK; Vidoni ED Alzheimers Dement; 2017 Sep; 13(9):1024-1030. PubMed ID: 28263740 [TBL] [Abstract][Full Text] [Related]
5. Associations of Widowhood and β-Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults. Biddle KD; Jacobs HIL; d'Oleire Uquillas F; Zide BS; Kirn DR; Properzi MR; Rentz DM; Johnson KA; Sperling RA; Donovan NJ JAMA Netw Open; 2020 Feb; 3(2):e200121. PubMed ID: 32101313 [TBL] [Abstract][Full Text] [Related]
6. Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time. Kuhn E; Moulinet I; Perrotin A; La Joie R; Landeau B; Tomadesso C; Bejanin A; Sherif S; De La Sayette V; Desgranges B; Vivien D; Poisnel G; Chételat G Alzheimers Res Ther; 2019 Jul; 11(1):61. PubMed ID: 31286994 [TBL] [Abstract][Full Text] [Related]
7. Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study. Hong YJ; Ho S; Jeong JH; Park KH; Kim S; Wang MJ; Choi SH; Yang DW; Alzheimers Res Ther; 2023 Aug; 15(1):132. PubMed ID: 37550761 [TBL] [Abstract][Full Text] [Related]
8. Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging. Valech N; Mollica MA; Olives J; Tort A; Fortea J; Lleo A; Belén SS; Molinuevo JL; Rami L J Alzheimers Dis; 2015 Sep; 48 Suppl 1():S87-98. PubMed ID: 26445275 [TBL] [Abstract][Full Text] [Related]
9. Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid? Akinci M; Sánchez-Benavides G; Brugulat-Serrat A; Peña-Gómez C; Palpatzis E; Shekari M; Deulofeu C; Fuentes-Julian S; Salvadó G; González-de-Echávarri JM; Suárez-Calvet M; Minguillón C; Fauria K; Molinuevo JL; Gispert JD; Grau-Rivera O; Arenaza-Urquijo EM; Alzheimers Res Ther; 2022 Sep; 14(1):126. PubMed ID: 36068641 [TBL] [Abstract][Full Text] [Related]
10. Subjective cognitive complaints at age 70: associations with amyloid and mental health. Pavisic IM; Lu K; Keuss SE; James SN; Lane CA; Parker TD; Keshavan A; Buchanan SM; Murray-Smith H; Cash DM; Coath W; Wong A; Fox NC; Crutch SJ; Richards M; Schott JM J Neurol Neurosurg Psychiatry; 2021 Nov; 92(11):1215-1221. PubMed ID: 34035132 [TBL] [Abstract][Full Text] [Related]
11. Amyloid Plaques and Symptoms of Depression Links to Medical Help-Seeking due to Subjective Cognitive Decline. Espenes R; Kirsebom BE; Eriksson C; Waterloo K; Hessen E; Johnsen SH; Selnes P; Fladby T J Alzheimers Dis; 2020; 75(3):879-890. PubMed ID: 32333584 [TBL] [Abstract][Full Text] [Related]
12. Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Miebach L; Wolfsgruber S; Polcher A; Peters O; Menne F; Luther K; Incesoy E; Priller J; Spruth E; Altenstein S; Buerger K; Catak C; Janowitz D; Perneczky R; Utecht J; Laske C; Buchmann M; Schneider A; Fliessbach K; Kalbhen P; Heneka MT; Brosseron F; Spottke A; Roy N; Teipel SJ; Kilimann I; Wiltfang J; Bartels C; Düzel E; Dobisch L; Metzger C; Meiberth D; Ramirez A; Jessen F; Wagner M Alzheimers Res Ther; 2019 Jul; 11(1):66. PubMed ID: 31366409 [TBL] [Abstract][Full Text] [Related]
13. Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum. Kuhn E; Perrotin A; La Joie R; Touron E; Dautricourt S; Vanhoutte M; Vivien D; de La Sayette V; Chételat G; Neurology; 2023 Jun; 100(24):e2454-e2465. PubMed ID: 37085328 [TBL] [Abstract][Full Text] [Related]
14. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. Jansen WJ; Janssen O; Tijms BM; Vos SJB; Ossenkoppele R; Visser PJ; ; Aarsland D; Alcolea D; Altomare D; von Arnim C; Baiardi S; Baldeiras I; Barthel H; Bateman RJ; Van Berckel B; Binette AP; Blennow K; Boada M; Boecker H; Bottlaender M; den Braber A; Brooks DJ; Van Buchem MA; Camus V; Carill JM; Cerman J; Chen K; Chételat G; Chipi E; Cohen AD; Daniels A; Delarue M; Didic M; Drzezga A; Dubois B; Eckerström M; Ekblad LL; Engelborghs S; Epelbaum S; Fagan AM; Fan Y; Fladby T; Fleisher AS; Van der Flier WM; Förster S; Fortea J; Frederiksen KS; Freund-Levi Y; Frings L; Frisoni GB; Fröhlich L; Gabryelewicz T; Gertz HJ; Gill KD; Gkatzima O; Gómez-Tortosa E; Grimmer T; Guedj E; Habeck CG; Hampel H; Handels R; Hansson O; Hausner L; Hellwig S; Heneka MT; Herukka SK; Hildebrandt H; Hodges J; Hort J; Huang CC; Iriondo AJ; Itoh Y; Ivanoiu A; Jagust WJ; Jessen F; Johannsen P; Johnson KA; Kandimalla R; Kapaki EN; Kern S; Kilander L; Klimkowicz-Mrowiec A; Klunk WE; Koglin N; Kornhuber J; Kramberger MG; Kuo HC; Van Laere K; Landau SM; Landeau B; Lee DY; de Leon M; Leyton CE; Lin KJ; Lleó A; Löwenmark M; Madsen K; Maier W; Marcusson J; Marquié M; Martinez-Lage P; Maserejian N; Mattsson N; de Mendonça A; Meyer PT; Miller BL; Minatani S; Mintun MA; Mok VCT; Molinuevo JL; Morbelli SD; Morris JC; Mroczko B; Na DL; Newberg A; Nobili F; Nordberg A; Olde Rikkert MGM; de Oliveira CR; Olivieri P; Orellana A; Paraskevas G; Parchi P; Pardini M; Parnetti L; Peters O; Poirier J; Popp J; Prabhakar S; Rabinovici GD; Ramakers IH; Rami L; Reiman EM; Rinne JO; Rodrigue KM; Rodríguez-Rodriguez E; Roe CM; Rosa-Neto P; Rosen HJ; Rot U; Rowe CC; Rüther E; Ruiz A; Sabri O; Sakhardande J; Sánchez-Juan P; Sando SB; Santana I; Sarazin M; Scheltens P; Schröder J; Selnes P; Seo SW; Silva D; Skoog I; Snyder PJ; Soininen H; Sollberger M; Sperling RA; Spiru L; Stern Y; Stomrud E; Takeda A; Teichmann M; Teunissen CE; Thompson LI; Tomassen J; Tsolaki M; Vandenberghe R; Verbeek MM; Verhey FRJ; Villemagne V; Villeneuve S; Vogelgsang J; Waldemar G; Wallin A; Wallin ÅK; Wiltfang J; Wolk DA; Yen TC; Zboch M; Zetterberg H JAMA Neurol; 2022 Mar; 79(3):228-243. PubMed ID: 35099509 [TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias. Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593 [TBL] [Abstract][Full Text] [Related]